Quinaprilat induces arterial vasodilation mediated by nitric oxide in humans

Hypertension

Volumn 30, Issue 4, 1997, Pages 912-917

  Haefeli, Walter E ^a,b   Linder, Lilly ^a   Lüscher, Thomas F ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Angiotensin converting enzyme inhibition; Bradykinin; Nitric oxide; Vascular resistance; Vasodilation

Indexed keywords

BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL MALEATE; ENALAPRILAT; NITRIC OXIDE; NITROPRUSSIDE SODIUM; QUINAPRILAT;

ADULT; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; FEMALE; FOREARM BLOOD FLOW; HUMAN; HUMAN EXPERIMENT; INTRAARTERIAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; VEIN OCCLUSION PLETHYSMOGRAPHY;

EID: 0030777363     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.30.4.912     Document Type: Article

References (39)

1. AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
3. Sakaguchi K, Chai SY, Jackson B, Johnston CI, Mendelsohn FA. Inhibition of tissue angiotensin converting enzyme: quantitation by autoradiography. Hypertension. 1988;11:230-238.
4. Taddei S, Favilla S, Duranti P, Simonini N, Salvetti A. Vascular renin angiotensin system and neurotransmission in hypertensive persons. Hypertension. 1991;18:266-277.
5. Zanzinger J, Zheng X, Bassenge E. Endothelium dependent vasomotor responses to endogenous agonists are potentiated following ACE inhibition by a bradykinin dependent mechanism. Cardiovasc Res. 1994;28:209-214.
6. Wiemer G, Schölkens BA, Becker RMA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 1991;18:558-563.
7. Erdös EG, Skidgel RA. The unusual substrate specificity and the distribution of human angiotensin I converting enzyme. Hypertension. 1986;8(suppl I):I-34-I-37.
8. Dorer FE, Kahn JR, Lentz KE, Skeggs LT. Hydrolysis of bradykinin by angiotensin-converting enzyme. Circ Res. 1974;34: 824-827.
9. Cascieri MA, Bull HG, Mumford RA, Patchett AA, Thornberry NA, Liang T. Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by captopril and MK-422. Mol Pharmacol. 1983;25:287-293.
10. Auch-Schwelk C, Bossaller C, Claus M, Graf K, Gräfe M, Fleck E. Local potentiation of bradykinin-induced vasodilation by converting-enzyme inhibition in isolated coronary arteries. J Cardiovasc Pharmacol. 1992;20(suppl 9):S62-S67.
11. Mombouli J-V, Vanhoutte PM. Heterogeneity of endothelium-dependent vasodilator effects of angiotensin-converting inhibitors: role of bradykinin generation during ACE inhibition. J Cardiovasc Pharmacol. 1992;20(suppl 9):S74-S83.
12. Benjamin N, Cockcroft JR, Collier JG, Dollery CT, Ritter JM, Webb DJ. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol. 1989;412:543-555.
13. Bönner G, Presi S, Schunk U, Wagmann M, Chrosch R, Toussaint C. Effect of bradykinin on arteries and veins in systemic and pulmonary circulation. J Cardiovasc Pharmacol. 1992;20(suppl 9): S21-S27.
14. Kiowski W, Linder L, Kleinbloesem C, van Brummelen P, Bühler FR. Blood pressure control by the renin-angiotensin system in normotensive subjects: assessment by angiotensin converting enzyme and renin inhibition. Circulation. 1992;85:1-8.
15. Farhy RD, Ho KL, Carretero OA, Scicli AG. Kinins mediate the antiproliferative effect of ramipril in rat carotid artery. Biochem Biophys Res Comm. 1992;182:283-288.
16. Hecker M, Bara AT, Busse R. Relaxation of isolated coronary arteries by angiotensin-converting enzyme inhibitors: role of endothelium-derived kinins. J Vasc Res. 1993;30:257-262.
17. 2-bradykinin receptor antagonist Hoe 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol. 1992;105:771-772.
18. Linz W, Schölkens BA. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol. 1992;20(suppl 9):S83-S90.
19. Johnston CI, Jandeleit K, Mooser V, Katapothis A, Perich R, Paxton D, Murohara Y, Jackson B. Angiotensin-converting enzyme and its inhibition in the heart and blood vessels. J Cardiovasc Pharmacol. 1992;20(suppl B):S6-S11.
20. Linder L, Kiowski W, Bühler FR, Lüscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response in essential hypertension. Circulation. 1990;81:1762-1767.
21. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 1989;2: 997-1000.
22. Dachman W, Ford GA, Blaschke TF, Hoffman BB. Mechanism of bradykinin-induced venodilation in humans. J Cardiovasc Pharmacol. 1993;21:241-248.
23. Welches WR, Brosnihan B, Ferrario CM. Minireview - a comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin-converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci. 1993;52: 1461-1480.
24. G-monomethyl-L-arginine on kinin-induced vasodilation in the human forearm. Br J Clin Pharmacol. 1994;38:307-310.
25. Meyer P, Flammer J, Lüscher TF. Local action of the renin angiotensin system in the porcine ophthalmic circulation: effects of ACE-inhibitors and angiotensin receptor antagonists. Invest Ophthalmol Vis Sci. 1995;36:555-562.
26. G-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm. Br J Clin Pharmacol. 1994;38: 311-315.
27. Nakamura M, Funakoshi T, Yoshida H, Arakawa N, Suzuki T, Hiramori K. Endothelium-dependent vasodilation is augmented by angiotensin converting enzyme inhibitors in healthy volunteers. J Cardiovasc Pharmacol. 1992;20:949-954.
28. Hecker M, Dambacher T, Busse R. Role of endothelium-derived bradykinin in the control of vascular tone. J Cardiovasc Pharmacol. 1992;20(suppl 9):S55-S61.
29. Van Wijngaarden J, Tio RA, van Gilst WH, de Graeff PA, de Langen CDJ, Wesseling H. Coronary vasodilation induced by captopril and zifenoprilat: evidence for a prostaglandin-independent mechanism. Naunyn Schmiedeberg's Arch Pharmacol. 1991;343: 491-495,
30. Webb DJ, Collier JG. Vascular angiotensin conversion in humans. J Cardiovasc Pharmacol. 1986;8(suppl 10):S40-S44.
31. Eichler H-G, Blöchl-Daum B, Kyrle PA, Gasic S. Cilazapril and enalapril inhibit local angiotensin I conversion in human veins but lack direct venodilating properties. J Cardiovasc Pharmacol. 1989; 14:248-252.
32. Zarnke KB, Feldman RD. Direct angiotensin converting enzyme inhibitor-mediated venodilation. Clin Pharmacol Ther. 1996;59: 559-568.
33. Dickstein K, Gottlieb S, Fleck E, Kostis J, Levine B, DeKock M, LeJemtel T. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J Hypertens. 1994;12(suppl 2):S31-S35.
34. Busse R, Pohl U, Mülsch A, Bassenge E. Modulation of the vasodilator action of SIN-1 by the endothelium. J Cardiovasc Pharmacol. 1989;14(suppl 11):S81-S85.
35. Kojda G, Beck JK, Meyer W, Noack E. Nitrovasodilator-induced relaxation and tolerance development in porcine vena cordis magna: dependence on intact endothelium. Br J Pharmacol. 1994; 112:533-540.
36. Moncada S, Rees DD, Schulz R, Palmer RMJ. Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci U S A. 1991;88:2166-2170.
37. Shirasaki Y, Su C. Endothelium removal augments vasodilation by sodium nitroprusside and sodium nitrite. Eur J Pharmacol. 1985; 114:93-96.
38. Lüscher TF, Richard V, Yang Z. Interaction between endothelium-derived nitric oxide and SIN-1 in human and porcine blood vessels. J Cardiovasc Pharmacol. 1989;14(suppl 11):S76-S80.
39. Pohl U, Busse R. Endothelium-derived relaxant factor inhibits the effect of nitrocompounds in isolated arteries. Am J Physiol. 1987; 252:H307-H313,